Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 2 completed trials

    Completion Rate
    100%(2/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 2
    1
    50%
    Phase 2/3
    1
    50%

    Phase Distribution

    0

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 2/3Combined phases
    1(50.0%)

    Highest Phase Reached

    Phase 2/3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    2 of 2 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(2)

    Detailed Status

    Completed2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2/3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 2/31 (50.0%)

    Trials by Status

    completed2100%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completedphase_2_3

    Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.

    NCT01941329
    completedphase_2

    Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

    NCT01280929

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT01941329Phase 2/3

    Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.

    Completed
    NCT01280929Phase 2

    Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

    Completed

    All 2 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    2